Loading...

Miltenberger Promoted to Chief of Staff

August 24, 2017  – Janesville, WI – SHINE Medical Technologies, Inc. (SHINE), a company dedicated to being the world leader in the safe, clean, affordable production of medical isotopes, announced today that Steve Miltenberger has been promoted to Chief of Staff. The announcement comes as the company prepares to build its facility in Janesville, Wisconsin, after receiving its construction permit from the U.S. Nuclear Regulatory Commission last year.  The SHINE facility will produce molybdenum-99 (moly‑99) and other medical isotopes used to detect and treat a wide variety of diseases, including heart disease and cancer.

SHINE Medical Technologies, Inc. (SHINE), a company dedicated to being the world leader in the safe, clean, affordable production of medical isotopes, announced today that Steve Miltenberger has been promoted to Chief of Staff for CEO Greg Piefer. The announcement comes as the company prepares to build its facility in Janesville, Wisconsin, after receiving its construction permit from the U.S. Nuclear Regulatory Commission last year. The SHINE facility will produce molybdenum-99 (moly-99) and other medical isotopes used to detect and treat a wide variety of diseases, including heart disease and cancer.

Mr. Miltenberger has over 30 years of nuclear industry experience in engineering, construction, and operations. His experience includes taking nine separate projects from new plant construction into operation.

Mr. Miltenberger’s role at SHINE is to move the project plan through construction and into commercial operation. This includes coordinating the engineering, construction, and operations teams with a focus on schedule and budget.

Prior to joining SHINE, Mr. Miltenberger served as the Head of Project Management for URENCO USA, Louisiana Energy Services. In this role, he was responsible for design, procurement, and construction for over $2 billion in assets at URENCO’s uranium enrichment plant. Mr. Miltenberger successfully implemented Phases 2 and 3 of the site project in Eunice, New Mexico, on schedule and on budget.

Mr. Miltenberger has a Bachelor’s degree in Electrical Engineering and a Master’s degree in Nuclear Engineering from the University of Missouri at Rolla. He is a Certified Senior Reactor Operator and a Professional Engineer in the states of Missouri, North Carolina, and New Jersey.

About Moly-99

Molybdenum-99 (moly-99) is a radioisotope that decays into the diagnostic imaging agent technetium‑99m (Tc-99m). Tc-99m is used in more than 40 million medical imaging procedures each year, primarily in stress tests to diagnose heart disease and bone scans to stage cancer. SHINE was founded to deploy a safe, cost-effective and environmentally friendly technology to produce medical isotopes, including moly‑99.

About SHINE Medical Technologies, Inc.

Founded in 2010, SHINE is a development-stage company working toward becoming a manufacturer of radioisotopes for nuclear medicine. The SHINE system uses a patented, proprietary manufacturing process that offers major advantages over existing and proposed production technologies, as it does not require a nuclear reactor, uses less electricity, generates less waste and is compatible with the nation’s existing supply chain for molybdenum-99. In 2014, SHINE announced the execution of molybdenum-99 supply agreements with GE Healthcare and Lantheus Medical Imaging. In 2015, with the help of Argonne National Laboratory, GE Healthcare demonstrated SHINE molybdenum-99 can act as a drop-in replacement for reactor-based moly-99.  In June of 2016, SHINE signed a moly-99 supply agreement with HTA Co., Ltd., the largest Chinese distributor of radiopharmaceuticals.  Learn more at http://shinemed.com.

2017-08-24T15:24:42+00:00